Department of Pediatrics, Hematology and Oncology, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Toruń, Bydgoszcz, Poland.
Department of Internal Medicine, Connective Tissue Diseases and Geriatrics, Medical University of Gdansk, Gdansk, Poland.
Front Immunol. 2022 Sep 23;13:953700. doi: 10.3389/fimmu.2022.953700. eCollection 2022.
At the beginning of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, patients with inborn errors of immunity (IEI) appeared to be particularly vulnerable to a severe course of the disease. It quickly turned out that only some IEI groups are associated with a high risk of severe infection. However, data on the course of Coronavirus Disease 2019 (COVID-19) in patients with IEI are still insufficient, especially in children; hence, further analyses are required. The retrospective study included 155 unvaccinated people with IEI: 105 children and 50 adults (67.7% and 32.3%, respectively). Male patients dominated in the study group (94 people, 60.6%). At least two comorbidities were found in 50 patients (32.3%), significantly more often in adults (56% vs. 21%). Adult patients presented significantly more COVID-19 symptoms. Asymptomatic and mildly symptomatic course of COVID-19 was demonstrated in 74.8% of the entire group, significantly more often in children (88.6% vs. 46%). Moderate and severe courses dominated in adults (54% vs. 11.4%). Systemic antibiotic therapy was used the most frequently, especially in adults (60% vs. 14.3%). COVID-19-specific therapy was used almost exclusively in adults. In the whole group, complications occurred in 14.2% of patients, significantly more often in adults (30% vs. 6.7%). In the pediatric group, there were two cases (1.9%) of multisystem inflammatory syndrome in children. Deaths were reported only in the adult population and accounted for 3.9% of the entire study group. The death rate for all adults was 12%, 15.4% for adults diagnosed with common variable immunodeficiency, 12.5% for those with X-linked agammaglobulinemia, and 21.4% for patients with comorbidity. The results of our study imply that vaccinations against COVID-19 should be recommended both for children and adults with IEI. Postexposure prophylaxis and early antiviral and anti-SARS-CoV-2 antibody-based therapies should be considered in adults with IEI, especially in those with severe humoral immune deficiencies and comorbidity.
在严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 大流行之初,患有先天性免疫缺陷 (IEI) 的患者似乎特别容易出现严重疾病。很快就发现,只有一些 IEI 群体与严重感染的高风险相关。然而,关于 IEI 患者 2019 年冠状病毒病 (COVID-19) 的病程的数据仍然不足,尤其是在儿童中;因此,需要进一步分析。这项回顾性研究包括 155 名未接种疫苗的 IEI 患者:105 名儿童和 50 名成人(分别为 67.7%和 32.3%)。男性患者在研究组中占主导地位(94 人,60.6%)。在 50 名患者中发现至少有两种合并症(32.3%),成人中明显更多(56%比 21%)。成人患者表现出更多的 COVID-19 症状。整个组中无症状和轻度症状的 COVID-19 病程占 74.8%,儿童中明显更多(88.6%比 46%)。中度和重度病程在成人中占主导地位(54%比 11.4%)。全身抗生素治疗最常用,尤其是在成人中(60%比 14.3%)。COVID-19 特异性治疗几乎仅在成人中使用。在整个组中,14.2%的患者出现并发症,成人中明显更多(30%比 6.7%)。在儿科组中,有两例(1.9%)儿童多系统炎症综合征。仅在成年人群中报告死亡,占整个研究组的 3.9%。所有成年人的死亡率为 12%,普通可变免疫缺陷的成年人为 15.4%,X 连锁无丙种球蛋白血症的成年人为 12.5%,合并症的成年人为 21.4%。我们的研究结果表明,IEI 儿童和成人均应推荐接种 COVID-19 疫苗。IEI 成人应考虑暴露后预防以及早期抗病毒和抗 SARS-CoV-2 抗体治疗,尤其是严重体液免疫缺陷和合并症患者。